Hem/Onc Roundup: Optimizing Treatment for Childhood Leukemia, New ASCO Guidelines, and More

Each week on DocWire, editors bring you the latest news and research in hematology and oncology. Here are this week’s top headlines:

Expert Discusses Phenotypic Precision Medicine in Advanced Prostate Cancer

This week on DocWire, editors spoke with Dr. Daniel Spratt, Radiation Oncology Chair at the University Hospitals Seidman Cancer Center, about phenotypic precision medicine in advanced prostate cancer. “It hasn’t been really until the past couple years that prostate cancer finally has really had precision medicine tools, especially in advanced prostate cancer, and so we’re really entering a new era, both from precision imaging as well as precision genetic markers,” said Dr. Spratt. Watch the full interview for more insights from Dr. Spratt, or visit the Phenotypic Precision Medicine in Prostate Cancer Knowledge Hub on GU Oncology Now.

Dr. Daniel Spratt Discusses Phenotypic Precision Medicine in Advanced Prostate Cancer

Optimizing Treatment for Childhood ALL

In other news, results from an international collaboration between the St. Jude’s Children’s Research Hospital and the Chinese Children’s Cancer Group found that children with low-risk acute lymphoblastic leukemia (ALL) may be able to safely skip maintenance therapy after their first year of treatment. There was no difference in five-year event-free survival between children with low-risk ALL who did or did not receive pulse therapy with vincristine plus dexamethasone after previously achieving remission.

“These findings are very good news for patients and families,” said corresponding authors Ching-Hon Pui, MD, “because shortening this pulse therapy will substantially reduce neuropsychological side effects, emotional disturbances and many other neurological and metabolic late effects.”


Global Study of Gastric Cancer Risk in Adults Under 40

A study in JAMA Network Open found that the incidence of gastric cancer has increased in people aged ≤40 years since 1980 in some countries. Incidence in younger adults increased for men in Sweden, women in Ecuador, and men and women in the United Kingdom. There was an overall global decrease in gastric cancer incidence in mortality since 1980.

Eastern Asia had the highest cumulative risk of gastric cancer incidence (2.64 percent) and mortality (1.84 percent). Southern Africa had the lowest risk of incidence (0.42 percent). Micronesia had the lowest risk of mortality (0.21 percent). There was a trend toward higher risk in countries with a higher Human Development Index.

New Study Assesses Risk of Gastric Cancer in Adults Under 40

ASCO Updates Recommendations for Managing Hereditary Breast Cancer

Finally, the American Society for Clinical Oncology (ASCO) updated their recommendations for managing hereditary breast cancer. According to the new rule, one year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy.

According to the updated recommendation, one year of adjuvant olaparib should be offered after completion of (neo)adjuvant chemotherapy and local treatment, including radiation, for patients with early-stage, HER2-negative breast cancer with a high risk for recurrence and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants.

ASCO Updates Recommendations for Managing Hereditary Breast Cancer